title: The role of active vaccination in cancer immunotherapy: lessons from clinical trials.
abstract: In the past few years, a number of different immunotherapeutic strategies have shown impressive results in cancer patients. These successful approaches include blockade of immunosuppressive molecules like PD-1 and CTLA-4, adoptive transfer of patient derived and genetically modified T-cells, and vaccines that stimulate tumor antigen specific T-cells. However, several large vaccine trials recently failed to reach designated primary endpoints. In light of the success of other immunotherapeutic approaches, these negative results raise the questions of why vaccines have not generated a better response, and what the role of active vaccination will be moving forward in cancer immunotherapy.
authors.affiliation: Department of Urology, Emory University School of Medicine, United States; Department of Microbiology and Immunology, Emory University School of Medicine, United States. Electronic address: haydn.kissick@emory.edu.
authors.forename: Haydn T
authors.initials: HT
authors.lastname: Kissick
authors.affiliation: Department of Urology, Emory University School of Medicine, United States.
authors.forename: Martin G
authors.initials: MG
authors.lastname: Sanda
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D008213:Lymphocyte Activation; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D058996:Quality Improvement; D013601:T-Lymphocytes / Q000276:immunology*; D016896:Treatment Outcome; D014611:Vaccination
chemical_list: D019138:Antibodies, Blocking; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor